<DOC>
	<DOCNO>NCT00925249</DOCNO>
	<brief_summary>This research help doctor interested usefulness new test discover hide tuberculosis infection patient diagnose rheumatoid arthritis ( RA ) . This new test call Quantiferon-Gold ( QFT-G ) . After immune system medicine block TNF-alpha ( protein manufacture white blood cell stimulate activate immune system response infection cancer ) start use , rate tuberculosis infection patient treated medicine increase . Doctors think investigator may miss tuberculosis infection hide medicine start . This new QFT-G test might better diagnose hidden tuberculosis infection current tuberculosis skin test , also know PPD/TST . The investigator would like compare two test find good detect hidden infection . At time investigator measure strength patient 's immune system blood test . If consider TNF-alpha inhibitor medicine , get patient 's routine PPD/TST , investigator ask patient 's participation .</brief_summary>
	<brief_title>Comparison Tuberculin Skin Test ( TST ) QuantiFERON ®-TB Gold Test ( QFT-G ) In Patients With Rheumatoid Arthritis Being Considered Anti-TNF-Alpha Therapy</brief_title>
	<detailed_description>In recent year use biologic agent treatment rheumatic condition call question utility classic tuberculin skin test ( TST ) diagnosis latent tuberculosis infection ( LTBI ) . Current clinical rheumatology practice require potential candidate biologic therapy negative TST begin biologic therapy . But since TST time consuming , operator dependent , fraught error , may fail alert physician LTBI patient autoimmune disease pharmaceutical immunosuppression . Reactions intradermal antigen placement require many cellular interaction , chiefly must possess , sufficient number memory T cell , ability proliferate clone T cell specific antigen introduce , ability traffic effector cell local site . If component miss individual may unable mount type IV hypersensitivity ( DTH-IV ) reaction basis TST . While many recently compare performance new IFN-gamma release assay ( IGRAs ) like QuantiFERON-γ TB GOLD® ( QFT-G ) TST diagnosis LTBI , one investigate immunologic factor may affect result . Some postulate QFT-G may less affected immune-suppression TST patient rheumatoid arthritis ( RA ) . But recently call question significant number indeterminate QFT-G result see RA patient . Therefore , plan address two current clinical question . First , best screen strategy LTBI RA patient start biologic agent - TST , QFT-G ? Second , utility conduct immune competence test RA patient predict may unable generate positive TST and/or QFT-G . This observational exploratory pilot study compare normal matched control RA patient consider anti-TNF alpha therapy . We perform comprehensive evaluation immune system measure memory T cell number flow cytometry , ability memory T cell proliferate tuberculin antigen purify protein derivative ( PPD ) , phytohemagglutinin ( PHA ) antigen via lymphocyte proliferation assay QunatiFERON-CMI.™ We also investigate memory T cell traffic ability via intradermal PPD PHA antigen placement . Results QFT-G test compare TST emphasis result discordant . We attempt identify immunocompetence testing may help identify patient unable mount DTH-IV response . In order detect statistical difference specific test population use analysis variance continuous ordinal variable chi-square test ( Fisher exact test ) categorical data statistic . We hope contribute body literature regard best screen strategy LTBI patient RA , explore concept screen immune competence specific population , elucidated literature .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Study group : Any patient 18 year old diagnose RA ( American College Rheumatology ( ACR ) criterion ) consider de novo antiTNF alpha therapy invite participate study . Control group : Control subject patient 18 year old present Allergy/Immunology clinic routine TST . Study group : We exclude individual previous history know immunocompromising disease state unstable medical condition RA result overall poor health and/or protein calorie deprivation include : autoimmune disease oral steroid use past 3 day ( 4 halflives prednisone 14 hour ) inhale steroid use dose &gt; 2000 mg beclomethasone equivalent/day cancer [ solid organ blood ] radiation therapy prior three month bleed disorder chemotherapeutic agent transfusion blood product past 1 year history HIV chronic hepatitis malignancy transplant history chronic infection chronic renal failure current allergy treatment ( shot , antihistamine ) uncontrolled diabetes , inability provide inform consent also exclude individual immediate hypersensitivity TST/PPD PHA antigens previous severe local ulceration TST/PPD suspect active TB , previous TB treatment Control group : We exclude individual know history antiTNF alpha therapy . We also exclude patient history immunemodulatory ( DMARD ) therapy ( steroid , antiTNF agent , methotrexate , azathioprine , sulfasalazine , etc . ) within previous 12 month . Additionally exclude individual previous history TB TB therapy , diabetes mellitus , HIV , malignancy , hepatitis may influence dermal reaction PHA antigen ex vivo CMI activity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>TB</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>anti-TNF therapy</keyword>
	<keyword>biologic therapy</keyword>
	<keyword>quantiferon</keyword>
	<keyword>IGRA</keyword>
	<keyword>Newly diagnose rheumatoid arthritis ( RA ) Tricare system</keyword>
</DOC>